Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1989 Jul 22;299(6693):215–216. doi: 10.1136/bmj.299.6693.215

Benign prostatic hyperplasia: the best treatment.

G D Chisholm 1
PMCID: PMC1836932  PMID: 2475197

Full text

PDF
215

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aubrey D. A., Khosla T. The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH582) on benign prostatic hypertrophy. Br J Surg. 1971 Sep;58(9):648–652. doi: 10.1002/bjs.1800580904. [DOI] [PubMed] [Google Scholar]
  2. Ball A. J., Feneley R. C., Abrams P. H. The natural history of untreated "prostatism". Br J Urol. 1981 Dec;53(6):613–616. doi: 10.1111/j.1464-410x.1981.tb03273.x. [DOI] [PubMed] [Google Scholar]
  3. Cabot A. T. II. The Question of Castration for Enlarged Prostate. Ann Surg. 1896 Sep;24(3):265–309. doi: 10.1097/00000658-189607000-00036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caine M., Perlberg S., Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. J Urol. 1975 Oct;114(4):564–568. doi: 10.1016/s0022-5347(17)67083-6. [DOI] [PubMed] [Google Scholar]
  5. Caine M., Perlberg S., Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551–554. doi: 10.1111/j.1464-410x.1978.tb06210.x. [DOI] [PubMed] [Google Scholar]
  6. Castro J. E., Griffiths H. J., Edwards D. E. A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. Br J Surg. 1971 Jul;58(7):485–489. doi: 10.1002/bjs.1800580703. [DOI] [PubMed] [Google Scholar]
  7. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology. 1988 Dec;32(6 Suppl):27–31. [PubMed] [Google Scholar]
  8. Geller J., Nelson C. G., Albert J. D., Pratt C. Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy: double-blind study. Urology. 1979 Nov;14(5):467–474. doi: 10.1016/0090-4295(79)90177-8. [DOI] [PubMed] [Google Scholar]
  9. Glynn R. J., Campion E. W., Bouchard G. R., Silbert J. E. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985 Jan;121(1):78–90. [PubMed] [Google Scholar]
  10. Graversen P. H., Gasser T. C., Wasson J. H., Hinman F., Jr, Bruskewitz R. C. Controversies about indications for transurethral resection of the prostate. J Urol. 1989 Mar;141(3):475–481. doi: 10.1016/s0022-5347(17)40864-0. [DOI] [PubMed] [Google Scholar]
  11. Hedlund H., Andersson K. E., Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983 Aug;130(2):275–278. doi: 10.1016/s0022-5347(17)51106-4. [DOI] [PubMed] [Google Scholar]
  12. Kirby R. S., Coppinger S. W., Corcoran M. O., Chapple C. R., Flannigan M., Milroy E. J. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol. 1987 Aug;60(2):136–142. doi: 10.1111/j.1464-410x.1987.tb04950.x. [DOI] [PubMed] [Google Scholar]
  13. Lepor H., Baumann M., Shapiro E. The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. J Urol. 1988 Sep;140(3):664–667. doi: 10.1016/s0022-5347(17)41751-4. [DOI] [PubMed] [Google Scholar]
  14. Oesterling J. E., Juniewicz P. E., Walters J. R., Strandberg J. D., Steele R. E., Ewing L. L., Coffey D. S. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate. J Urol. 1988 Apr;139(4):832–839. doi: 10.1016/s0022-5347(17)42657-7. [DOI] [PubMed] [Google Scholar]
  15. Peters C. A., Walsh P. C. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 1987 Sep 3;317(10):599–604. doi: 10.1056/NEJM198709033171004. [DOI] [PubMed] [Google Scholar]
  16. Reddy P. K., Wasserman N., Castañeda F., Castañeda-Zuñiga W. R. Balloon dilatation of the prostate for treatment of benign hyperplasia. Urol Clin North Am. 1988 Aug;15(3):529–535. [PubMed] [Google Scholar]
  17. Roos N. P., Wennberg J. E., Malenka D. J., Fisher E. S., McPherson K., Andersen T. F., Cohen M. M., Ramsey E. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989 Apr 27;320(17):1120–1124. doi: 10.1056/NEJM198904273201705. [DOI] [PubMed] [Google Scholar]
  18. Scott W. W., Wade J. C. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol. 1969 Jan;101(1):81–85. doi: 10.1016/s0022-5347(17)62279-1. [DOI] [PubMed] [Google Scholar]
  19. Walsh P. C., Madden J. D., Harrod M. J., Goldstein J. L., MacDonald P. C., Wilson J. D. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974 Oct 31;291(18):944–949. doi: 10.1056/NEJM197410312911806. [DOI] [PubMed] [Google Scholar]
  20. Wenderoth U. K., George F. W., Wilson J. D. The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology. 1983 Aug;113(2):569–573. doi: 10.1210/endo-113-2-569. [DOI] [PubMed] [Google Scholar]
  21. Williams G., Jager R., McLoughlin J., el Din A., Machan L., Gill K., Asopa R., Adam A. Use of stents for treating obstruction of urinary outflow in patients unfit for surgery. BMJ. 1989 May 27;298(6685):1429–1429. doi: 10.1136/bmj.298.6685.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wilson J. D. The pathogenesis of benign prostatic hyperplasia. Am J Med. 1980 May;68(5):745–756. doi: 10.1016/0002-9343(80)90267-3. [DOI] [PubMed] [Google Scholar]
  23. Wilson J. D. The testes and the prostate: a continuing relationship. N Engl J Med. 1987 Sep 3;317(10):628–629. doi: 10.1056/NEJM198709033171010. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES